DadFinStart your free week
DadFin › Stocks › Healthcare › CRVO

CervoMed Inc. (CRVO) stock score

Healthcare · Biotechnology · United States

$1.67 ▼ -1.18% today

26.3
Dad Score, out of 100
weak

CervoMed Inc. (CRVO) is a Biotechnology company in the Healthcare sector, listed in the United States. On DadFin's weekly run it scores 26.3 out of 100 on the Dad Score, a weak reading that places the business ahead of 26% of the 5,684 US and Canadian stocks DadFin fully scores. Inside Healthcare it ranks #630 of 956. Its strongest axes are conviction and liquidity; its weakest are valuation and quality.

Scores from the run of Nov 15, 2026. The Dad Score answers one question: how good is this business, measured against its own sector. How it is built →

The eight axes

Valuation
Below average
Quality
Weak
Growth
Average
Price action
Average
Risk
Below average
Conviction
Above average
Liquidity
Strong
Macro
Average

Each axis is ranked inside the stock's own sector. Subscribers see the percentile and every input behind each bar.

Key numbers

P/E (trailing)—
P/E (forward)-1.4×
Dividend yield0.00%
Return on capital-148.0%
Operating margin-334924.9%
Revenue growth (YoY)+0.0%
FCF yield-135.3%
Net debt / EBITDA3.00×
Piotroski F-Score1 / 9
52-week change-79.4%
Market cap$26M
Next earningsMar 8, 2027

What subscribers see on CRVO

Start your free weekSubscriber? Open the full research →

Biotechnology peers

StockCompanyDad ScoreBandMarket cap
VRTXVertex Pharmaceuticals Incorporate75.0good$136.6B
REGNRegeneron Pharmaceuticals, Inc.98.6strong$98.8B
MRNAModerna, Inc.31.8weak$90.4B
ARGXargenx SE86.7strong$60.4B
ONCBeOne Medicines AG95.0strong$47.6B
RPRXRoyalty Pharma plc98.2strong$39.9B
RVMDRevolution Medicines, Inc.44.8middling$37.3B
GMABGenmab A/S63.2middling$31.7B

Prices from DadFin's live feed (refreshed about every 30 minutes in the session); scores from the weekly run of Nov 15, 2026. Fundamentals as reported in the latest filings. Research, not investment advice.